publication date: Sep. 13, 2019
Issue 34 - Sep. 13, 2019
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Guest Editorial

    Why CAR-T policymaking is broken, and why we need to fix it

    The initial reports of the near-miraculous benefits of CAR-T in pediatric acute lymphoblastic leukemia generated tremendous excitement—there was a Lazarus-like quality to these stories.

  • The 2019 Lasker Awards go to: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance

    The Lasker Foundation has named the winners of the 2019 Lasker Awards: Max D. Cooper, Jacques Miller, Michael Shepard, Dennis J. Slamon, Axel Ullrich, and Gavi, the Vaccine Alliance.

  • In Brief

    • DeAngelis named MSK physician-in-chief, chief medical officer
    • Bondy named chair of Stanford Epidemiology and Population Health Department
    • Farrar named CEO at Ohio State James Cancer Hospital and Solove Research Institute 
    • Yang appointed director of Division of Hematology at Ohio State 
    • Patierno receives AACR Distinguished Lectureship on the Science of Cancer Health Disparities
    • Samuel Waxman Cancer Research Foundation awards $1.4 million in grants
    • Purdue and Frederick National Laboratory form partnership focused on big data approach to cancer 
    • Bauml, Lai, and Lisberg receive LUNGevity 2019 Career Development Awards
    • UMN researchers awarded grant in metastatic breast cancer
    • Fortin departs Winship for UCLA Health
  • TCCL Logo

  • Conversation with The Cancer Letter

    Michigan’s Philip Stella receives NCORP 2019 Harry Hynes Award

    Philip J. Stella, the principal investigator of the Michigan Cancer Research Consortium NCI Community Oncology Research Program site in Ann Arbor, won the 2019 Harry Hynes Award.

  • Clinical Roundup

    • IMFINZI is first immunotherapy to show OS benefit,  improved, durable responses in extensive-stage SCLC 
    • Pooled five-year survival results show OS advantage for Opdivo in advanced NSCLC 
    • LOXO-292 shows 68% ORR, sustained durability in heavily pretreated RET fusion-positive NSCLC
    • ASTRO guideline clarifies role of radiation therapy in pancreatic cancer treatment
    • Study shows higher risk of death in patients with CV conditions who receive novel oral prostate cancer therapies 
  • Drugs & Targets

    • Adaptimmune receives Orphan Drug Designation for SPEAR T-cells targeting MAGE4-A in soft tissue sarcoma 
    • BioXcel receives Orphan Drug Designation for BXCL701 in AML

Copyright (c) 2020 The Cancer Letter Inc.